PTGES3 Identified as Key Regulator of Androgen Receptor in Prostate Cancer

TL;DR
Genome-scale CRISPR screens identified PTGES3 as a key regulator of androgen receptor (AR) stability and activity in advanced prostate cancer, revealing its potential as a therapeutic target to overcome resistance to AR-targeted therapies in castration-resistant prostate cancer (CRPC).
Topics:healthcancer-research#androgen-receptor#cancer-research#crispr-screens#prostate-cancer#ptges3#therapy-resistance
Want the full story? Read the original reporting
Read on Nature